Company
Swedish Orphan
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
3
3 still marketed
Novel approvals
2
Approvals since 2021
0
Originals and new uses
Phase 3 trials
21
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsPivotal-lookingRecruiting
Swedish Orphan BiovitrumIndustry
NCT07898774 · 30 participants (planned) · Start Jan 21, 2027 · Primary completion Jan 17, 2031
Drug: Pegcetacoplan · For: C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN); Recurrent Glomerular Disease After Kidney Transplantation
Sites: Recife, Brazil; Botucatu, Brazil; São Paulo, Brazil · 33 sites in all
Marketed drugs (3)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.